Dio Corp (039840) 2026 outlook: the DIOnavi full-digital implant moat and export growth versus the China VBP pricing shock, US channel, FX, and competition from Osstem, Dentium, Straumann.
INSP (Inspire Medical Systems) 2026 stock outlook. A deep qualitative look at the hypoglossal nerve stimulation implant for obstructive sleep apnea (OSA), the razor-and-blade growth model, the clinical-evidence and reimbursement and hospital-adoption moat, CPAP-intolerant market penetration, the GLP-1 weight-loss threat, Nyxoah competition, and the path to profitability.
i-SENS (099190) 2026 stock outlook. A deep qualitative look at the self-monitoring blood glucose (BGM) cash cow, the continuous glucose monitor (CGM) localization and reimbursement growth option, the electrochemical biosensor platform, overseas OEM supply, competition from Abbott Libre and Dexcom, CGM investment losses, and currency risk.
GKOS (Glaukos) 2026 stock outlook. A deep qualitative look at its glaucoma MIGS leadership with iStent, the iDose sustained drug-delivery pivot, the Epioxa corneal-disease pipeline, and the reimbursement, competition, and cash-burn growth-stock risks.
PEN (Penumbra) 2026 stock outlook. A qualitative deep dive into aspiration thrombectomy for stroke, peripheral CAVT, the single-use catheter razor-and-blade model, recall and valuation risk, and Stryker and Medtronic competition.
Vatech (KOSDAQ 043150) 2026 stock outlook for foreign investors. A qualitative deep dive into its 3D cone-beam CT, panoramic X-ray and intraoral scanner lineup, the analog-to-digital dentistry shift, AI-reading software and consumable recurring revenue, plus risks from dental capex cyclicality, currency swings and competition from Dentsply Sirona and Planmeca.
Teleflex (TFX) 2026 stock analysis: recurring single-use device revenue across catheters, vascular access, and UroLift, the planned separation of Urology, Acute Care and OEM, the BIOTRONIK vascular deal, UroLift's growth debate, and margins funding deleveraging.
Nordson (NDSN) 2026 stock analysis: the precision adhesive and coatings dispensing moat, the three-segment structure spanning electronics test and inspection and medical fluid components, why recurring consumables revenue cushions the cycle, NBS-driven M&A compounding, and the electronics-cycle and valuation risks.
Interojo (KOSDAQ 119610) stock outlook for 2026. A qualitative deep dive into its silicone hydrogel one-day and color contact lens ODM edge, the Clalen own-brand, export expansion into Japan, Europe and the Middle East, the capacity build cycle, and FX leverage for foreign investors.
Globus Medical (GMED) 2026 stock analysis: the ExcelsiusGPS razor-blade robotics model, NuVasive merger synergies versus sales-force disruption, trauma and orthopedics expansion, and heavyweight competition from Medtronic and Stryker.
Jeisys Medical (287410) 2026 stock outlook. A deep qualitative look at its RF and HIFU energy-based devices, the recurring consumable-tip revenue model, POTENZA export momentum, the three-way fight with Classys and Wontech, ownership and M&A risk, and the metrics that actually move this KOSDAQ aesthetic name.
InBody (KOSDAQ 041830) 2026 stock analysis for global investors: the world's leading body composition analyzer brand, B2B install base at hospitals and gyms, consumables and subscription recurring revenue, high overseas sales, net-cash balance sheet, and the FX, growth, and new-business risks.
West Pharmaceutical Services (WST) makes the stoppers, plungers, and seals inside injectable drug vials — and that regulatory design-in moat makes switching suppliers nearly impossible. Here's the long-term investment case, including biologics, GLP-1, and HVP mix tailwinds.
Align Technology (ALGN) 2026 stock analysis: Invisalign brand moat, iTero scanner razor-blade dynamics, patent expiry competition, teen expansion, and why this medtech trades like a consumer discretionary stock.
STERIS plc 2026 outlook: infection prevention, AST contract sterilization, life sciences — bull/base/bear scenarios, risks, and what to watch.
Becton Dickinson (NYSE: BDX) 2026 investment analysis — consumable-driven moat, Dividend Aristocrat track record, portfolio separation strategy, key risks, and how BD stacks up against Stryker, Medtronic, and peers.
Abbott Laboratories (ABT) stock outlook 2026. FreeStyle Libre CGM dominance, 4-segment diversification, 52-year dividend streak, 50% analyst upside, and price target scenarios for US investors.